Microglia: The Real Foe in HIV-1-Associated Neurocognitive Disorders?
2021
Ana Borrajo López | Maria Aránzazu Penedo | Tania Rivera-Baltanas | Daniel Pérez-Rodríguez | David Alonso-Crespo | Carlos Fernández-Pereira | José Manuel Olivares | Roberto Carlos Agís-Balboa
The current use of combined antiretroviral therapy (cART) is leading to a significant decrease in deaths and comorbidities associated with human immunodeficiency virus type 1 (HIV-1) infection. Nonetheless, none of these therapies can extinguish the virus from the long-lived cellular reservoir, including microglia, thereby representing an important obstacle to curing HIV. Microglia are the foremost cells infected by HIV-1 in the central nervous system (CNS) and are believed to be involved in the development of HIV-1-associated neurocognitive disorder (HAND). At present, the pathological mechanisms contributing to HAND remain unclear, but evidence suggests that removing these infected cells from the brain, as well as obtaining a better understanding of the specific molecular mechanisms of HIV-1 latency in these cells, should help in the design of new strategies to prevent HAND and achieve a cure for these diseases. The goal of this review was to study the current state of knowledge of the neuropathology and research models of HAND containing virus susceptible target cells (microglial cells) and potential pharmacological treatment approaches under investigation.
显示更多 [+] 显示较少 [-]